DBV Technologies SA - American (DBVT) Q3 2026 Earnings Report

The call was predominantly positive, centered on the completed 4-through-7 BLA submission, cash funding into the third quarter of 2027, progress toward commercial readiness, FDA engagement and continued advancement of the toddler program. However, the company still faces significant execution and regulatory dependencies, including Fareva's unresolved Warning Letter remediation, an unscheduled FDA reinspection, pending Priority Review decisions, uncertainty around the toddler BLA process and higher operating expenses.

DBV estimates that its existing cash will fund operations into the third quarter of 2027, expects to submit a toddler BLA in 2027, and included a PAI readiness target date after Fareva expects to have completed remediation, with February 1 shared with the FDA as the date it would be ready for an inspection; the company said it is planning for the best case scenario, which is a tight timeline, with no extra buffer time, and remains comfortable that all that can be managed within the clock of Priority Review. DBV said setting up a new facility takes about 3 years, is looking at a sales force of 50 to 70 people to target 4,500 allergists in the U.S., and said you launch a blockbuster on 18 months of preparation; it will not be providing guidance on first year sales potential.